South Korea approves EPIX' Vasovist

20 July 2008

EPIX Pharmaceuticals, a US biopharmaceutical company focused on discovering and developing therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, says that its novel blood pool magnetic resonance angiography agent, Vasovist (gadofosveset trisodium) has been approved for marketing in South Korea.

This is the 34th country (including all 27 members of the European Union, Switzerland, Turkey, Australia and Canada) outside the USA where this agent has been approved for marketing, said the firm's chief executive, Michael Kauffman. "We remain hopeful for approval of Vasovist in the USA by the end of 2008 and, as previously-announced, recently resubmitted a New Drug Application for Vasovist to the US Food and Drug Administration," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight